Health officials are reminding the public that antibiotics are ineffective against respiratory infections caused by viruses, ...

FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and ...

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

All flu vaccines for the 2024-25 season will be trivalent, meaning they protect against three different strains of influenza: ...

It's been more than a year since the Food and Drug Administration approved the first vaccine to treat RSV. Since then, newly ...

For older adults, respiratory syncytial virus (RSV) vaccination is effective against RSV hospitalization, according to a study published online Sept. 4 in the J ...

against respiratory syncytial virus and human rhinovirus in nasal epithelium in vitro and mice in vivo Overview Prophylactic intranasal RIG-101 demonstrates potent antiviral activities against human ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

Vaccination against respiratory syncytial virus for adults over 60 is likely to be cost-effective by preventing illness, ...

A normal respiratory rate for adults is between 12 to 18 breaths per minute. Normal respiratory rates for children depend on their age, with babies and toddlers taking more breaths per minute.

You will be able to get a free RSV vaccination because you’re aged 75 to 79 years (or recently turned 80). Every year, thousands of people in your age group need hospital care for RSV infection. RSV ...

Respiratory virus season is right around the corner. Although rates are still nowhere close to where they were during 2022’s omicron wave, percent positivity remains high and was higher in late ...